<u>Article title:</u> Plasma brain-derived tau: analytical and clinical validation of the first commercial

immunoassay

<u>Authors:</u> Michel N. Nafash[1,2,3], Sarah E. Svirsky[4], Xuemei Zeng[1,2,3], Yijun Chen[1,2,3,5], Julia K.

Kofler[3,6], Ann D. Cohen[1,3], David O. Okonkwo[4], Oscar L. Lopez[3,7], Ava M. Puccio[4#], Thomas K.

Karikari[1,2,3*#]

[1]Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[2]Biofluid Biomarker Laboratory, Western Psychiatric Hospital, University of Pittsburgh Medical

Center, Pittsburgh PA, USA

[3]Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh PA, USA

[4]Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh,

PA, USA

[5]Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA

[6]Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[7]Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[#]Joint senior authors

*Corresponding authors

<u>Corresponding Author:</u>

Thomas K. Karikari

UPMC Western Psychiatric Hospital

3811 O'Hara St.

Pittsburgh, PA 15213

Email: <u>karikaritk@upmc.edu</u>

Phone: +1 412 246 5395

Keywords: Brain-derived tau, Traumatic brain injury, Alzheimer's disease, Analytical validation,

Clinical validation, Blood-based biomarkers

26   **Abstract**

Background: Brain-derived tau (BD-tau) is a promising blood-based biomarker for

neurodegeneration/brain injury in neurodegenerative and acute neurological disorders.

However, widespread use is hampered by lack of commercial assays.

Methods: Using the Simoa® HD-X analyzer, we evaluated the first commercial research-use

only BD-tau Advantage PLUS assay's robustness, precision, dilution linearity, spike recovery,

specificity, and limits of detection. Matrix effect was examined by comparing BD-tau levels in

n=48 plasma/serum and n=20 plasma/CSF sample pairs. Clinical performance was examined in

a traumatic brain injury (TBI) cohort.

Results: Twenty repeated measurements of three plasma samples gave intra- and inter-plate

CVs ≤7.24%. A median drift of 8.00% (decrease) was observed from the start to the end of a full

plate run. Analytically, BD-tau concentrations decreased linearly up to 16-fold dilution, spike

recovery was 86-96%, and signals were highly specific to the CNS-abundant tau441 but not the

peripherally-enriched "big-tau" isoform. Moreover, signals were stable for up to four freeze/thaw

cycles. Furthermore, significant correlations were observed in the plasma/serum (r=0.8392;

p<0.0001) and plasma/CSF (r=0.6150; p=0.0039) pairs. Finally, plasma BD-tau was elevated in

severe-acute TBI vs. chronic-mixed TBI and unaffected controls (p<0.0001; AUC=0.9986, and

p<0.0001; AUC=1.000, respectively). In severe-acute TBI patients, plasma BD-tau was

correlated with plasma p-tau217 (r=0.5761, p=0.0005), NfL (r=0.8910, p=0.0001), and GFAP

(r=0.5424, p=0.0011). CSF BD-tau and CSF p-tau217 were strongly correlated (r=0.9667,

p=0.0002).

Conclusion: BD-tau Advantage PLUS produces robust brain-derived tau-specific readings that

demonstrate utility in detecting severe-acute TBI.

49   **Introduction**

Clinical care for neurological disorders is experiencing a shift towards the integration of

biomarkers into standard practices for diagnosis, tracking disease progression, and measuring

response to therapies [1]. A biomarker can be objectively quantified and, when thoroughly

validated, can act as a surrogate indicator of disease state and stage, as well as target

engagement and efficacy in therapeutic campaigns [1,2]. For example, in several

neurodegenerative diseases, cerebrospinal fluid (CSF) biomarkers have been incorporated into

clinical practice for over a decade in conditions like Alzheimer's disease (AD) and Parkinson

disease (PD) [3–8]. However, the utility of CSF biomarkers is limited by accessibility,

invasiveness, and cost concerns [9,10]. Blood-based biomarkers have seen a fast emergence

due to the ease of collection, affordability, and comparable performance to CSF biomarkers

[4,8,9,11,12].

A main limitation of blood-based biomarker assays for neurological disorders is the

potential contamination of blood measurements by protein forms in systemic circulation

originating from peripheral sources and not released from the central nervous system (CNS)

[6,13–16]. This issue affects the reliability of several prominent biomarkers when measured in

plasma including amyloid-beta (Aß) peptides, given their high levels in both CNS and non-CNS

sources such as platelets and the liver which compromises the fold change in plasma when

compared with levels in CSF [13]. A similar situation exists for tau protein which in addition to

being abundant in the CNS, is equally found in many non-CNS tissues including lungs, heart,

kidneys, muscles, and the peripheral nervous system [6,14–16]. This accounts, at least partly,

for why the neurodegeneration/brain injury biomarker total tau performs poorly in blood despite

its high accuracies in CSF, which show no correlations to blood-based measurements in AD

[6,17]. Therefore, optimization of blood-based biomarker assays to improve their selectivity for

CNS-originating proteins is needed to improve their accuracies and alignment with their CSF

biomarker assay counterparts while maintaining the integrity of their measurements.

In 2023, a blood-based assay referred to as brain-derived tau (BD-tau), which provides a

"barcoding" approach to select for tau protein released from the CNS, was reported [6]. The

main unique feature is that BD-tau uses a novel antibody combination that ensures signal

specificity to analytes only containing the six tau isoforms abundantly found in the adult human

brain vs. the higher molecular weight tau isoforms (containing the exon 4a insert) more

commonly released from the periphery (thus the name big-tau) [6]. Plasma/serum BD-tau levels

strongly correlated with CSF BD-tau and CSF total tau, outperforming blood-based total-tau in

this regard [6,18]. Moreover, plasma and serum BD-tau levels are strongly correlated [18].

In addition to showing strong correlations with other plasma and CSF biomarkers of AD

as well as with baseline and worsening cognitive decline, BD-tau levels were more related to

neurodegeneration in AD vs. non-AD neurodegenerative diseases, and appeared unaffected by

common comorbidities (e.g., diabetes) and *APOE ε4* carriership [6,19,20]. In addition,

plasma/serum BD-tau levels agree strongly with the severity of neurodegeneration/brain injury

have demonstrated clinical utility for rapidly progressive AD and Creutzfeldt-Jakob disease [21].

In severe traumatic brain injury (sTBI), initial BD-tau measurements at the time of and one week

after injury were more robustly correlated with worse clinical outcome scores than plasma total-

tau, p-tau231, NfL, showing the significance of CNS selective-tau in outcome prediction [22].

Finally, BD-tau shows a more coherent time-dependent pattern to predict outcome of traumatic

brain injury than both NfL and total-tau [22].

To date, BD-tau studies have been limited to using the original prototype assay. More

recently, a commercial version of the blood-based BD-tau measurement assay, the Quanterix®

BD-tau Advantage PLUS reagent kit, became available. However, independent analytical and

clinical validation is lacking. In this study, we performed analytical validation tests according to

the FDA's recommendations for bioanalytical method validation [23], as well as analytical

chemistry experts, on the aforementioned assay to ensure the accuracy and reliability of

measurements [24]. We also report validation of the assay in clinical severe TBI patients.

Materials and Methods

<u>Study Cohorts and Sample Collection</u>

Plasma samples used for validation experiments were collected from participants at the

University of Pittsburgh's Alzheimer's Disease Research Center (ADRC) into

ethylenediaminetetraacetic acid (EDTA) tubes. Samples were spun at 2000xg for 10 minutes at

4°C to separate plasma from whole blood, then aliquoted into microtubes and stored at -80°C

until time of use. Storage conditions for samples collected purposefully for assay stability

experiments differed from this protocol as highlighted in Supplemental Table 1. Additionally, a

pooled plasma sample commercially acquired from Precision for Medicine Bethesda, MD, USA

was aliquoted into 500µL single-use aliquots and stored at -80°C until needed. Plasma and

serum pairs were collected from the ADRC cohort following procedures described previously

[25] and stored at -80°C pending use. Biobanking measures followed standard guidelines [26].

Severe TBI participants were prospectively enrolled at admission between 2019-2024

through the Brain-Trauma Research Center at the University of Pittsburgh, Pittsburgh, PA, USA.

Eligibility was determined by the presence of severe TBI defined as Glasgow Coma Scale

(GCS) score <9 at enrollment and age 16–80 years. Exclusion criteria were penetrating brain

injury, brain death and pregnancy.

Chronic mixed TBI and control individuals were recruited through a Peer Reviewed

Alzheimer's Research Program (PRARP) study. Inclusion criteria for the chronic mixed TBI

group were: 1. History of at least one TBI that occurred over one year prior to enrollment; 2. Age

29-59 years; 3. Suspected cognitive impairment (based on neuropsychological assessment or

professional diagnosis of cognitive impairment). Exclusion criteria for the chronic mixed TBI

group were: 1. History of penetrating TBI, 2. history of pre-existing neurologic or

neurodegenerative disorder, 3. History of psychiatric disorder, 4. Active drug or alcohol

dependence, 5. Contraindication to magnetic resonance imaging or PET scans. Inclusion

criteria for the control group were age 29-59 years and a score less than 1 the Ascertain

Dementia 8 item Questionnaire (AD8), and exclusion criteria were a history of blast exposure or

moderate to severe TBI.

Blood was taken from an indwelling catheter placed as a routine standard of care using

6 mL K3EDTA tubes (Greiner Bio-One, Fischer Scientific). To isolate plasma, samples were

spun for 15 mins at 1500xg within 60 minutes of collection and aliquoted into cryovials for

storage at -80 °C. For the severe TBI group plasma collected on day 4 post-injury was used in

this study. For the chronic mixed TBI and control groups, baseline plasma was collected at time

of consent, using similar methods.

A subset of the chronic mixed TBI (n=7) and control subjects (n=7) had CSF collected by

lumbar puncture. CSF was collected from sTBI participants (n=9) using an indwelling

ventriculostomy catheter via external ventricular drainage. All samples were gently inverted to

avoid possible gradient effects, briefly centrifuged at low speed, and aliquoted into

polypropylene cryovials prior to freezing and storage at –80°C.

The Pittsburgh ADRC and the Brain-Trauma and PRARP TBI studies were reviewed and

approved by the Institutional Review Board at the University of Pittsburgh. The reference

numbers for approvals are as follows: ADRC study, MOD19110245-023; BTRC study,

19030228; Military CTE study, 19110161.

Data Collection

Data for this study were collected and analyzed at the University of Pittsburgh's Biofluid

Biomarker Laboratory between June 2024 and March 2025. Biomarker tests were run on

Quanterix® Simoa® HD-X analyzer using the Quanterix® BD-tau Adv PLUS reagent kit (Lots

504274 and 504275). All average enzymes per bead (AEB) and replicate concentration values

were acquired directly from instrument-generated exports, except for concentrations calculated

with the custom-generated universal calibration curve. Calibrators were run in either duplicates

or triplicates. We excluded calibrator H (60.0 pg/mL) after determining its non-importance for

estimating BD-tau concentrations in plasma and serum based on interpolating concentrations

with calibration curves using different subsets of calibrators.

<u>Experiment Procedures</u>

Analytical validation experimental procedures are described in Supplemental Appendix

1.1.

<u>Statistical Analyses</u>

All statistical analyses were performed in GraphPad Prism (v10.1.2(324)) and Microsoft

Excel (V2503 Build 16.0.18623.20266). Descriptive statistics, Spearman correlations, Friedman

and Dunn's multiple comparisons tests, and Kruskal-Wallis one-way ANOVA and multiple

comparison tests were conducted using GraphPad. Since data were not normally distributed,

non-parametric tests were used and the results presented as median (IQR) values. Prism was

also used for simple linear and 4-parameter logistic (4-PL) regression models, the latter being

used to generate the universal calibration curve. Microsoft Excel was used to organize the

preparation and results of tests such as dilution linearity and spike recovery, for normalization of

the precision and sample stability tests, and to apply the 4-PL model to generate assay

concentrations. For the lower limit of quantification (LLOQ) calculations, 4-PL parameters

generated by the instrument were used, whereas the universal calibration curve parameters

were acquired from GraphPad Prism's interpolation of the calibrator AEB data. Finally, QC

performance and calculation of the coefficients of variation (CV) were also done using MS

Excel.

<div align="center">**Results**</div>

<u>Cohort characteristics</u>

Characteristics of the participants (n=50) who provided the plasma/serum pairs have

been described previously [25]. Characteristics of the participants (n=63) of the pilot TBI cohort

are found in Supplemental Table 2.

<u>Assay details</u>

We used an eight-point calibration curve for the BD-tau assay, with seven non-blank

calibrators ranging from 0.246 pg/mL to 150 pg/mL. See Supplemental Figure 1 for a sample

calibration curve.

<u>Robustness and Precision</u>

We assessed the robustness, repeatability, and intermediate precision of the assay

under two different conditions. First, three QC samples with different BD-tau levels were used to

evaluate assay reproducibility. For samples analyzed on the same plate (n=10 independent

runs), the median CV for the high QC sample [median: 223 pg/mL (IQR: 207-227)] was 5.65%,

versus 5.23% and 7.03% for the medium and low QC samples [16.4 pg/mL (15.2-16.7)] and

[7.42 pg/mL (7.07-7.59), respectively]. These %CVs were within the widely accepted range of

<20% [24]. Furthermore, the median drift in signal from the start to the end of the same plate for

aliquots of identical QC samples was ~8.00% (range: 7.40-13.9%) [Figure 1A]. Overall assay

robustness was good with a %CV of up to ~7.24% for the pooled between-plate data [Figure

1B]. These results suggest that the assay is robust for independent measurements performed at

different times.

The second condition involved five different plasma samples that were measured 25

individual times, across five runs over five different days. For each sample evaluated, Figure 1C

shows the % plasma BD-tau levels normalized to the mean of all 25 measurements, used to

quantify repeatability and intermediate precision. The repeatability (CV_r) was 6.47%-12.4% and

the intermediate precision (CV_{Rw}) 9.52%-15.1% [Supplemental Table 3]. The measured

endogenous concentrations of each sample are shown in Figure 1D and Supplemental Table 2.

This set of results indicates that the assay is robust, and that results can be compared to one

another within the same batch/lot.

Limits of Quantification

AEB signals for 16 blank samples ranged between 4.290×10^{-3} and 8.740×10^{-3}

[Supplemental Table 4], with the mean and SD being 5.990×10^{-3} and 1.070×10^{-3}, respectively.

The LLOQ signal (mean + 10 standard deviations) becomes 0.0167, which gives an analytical

LLOQ of 0.0933 pg/mL when calculated according to Equation 1 [Supplemental Appendix 1.1.3].

The manufacturer's analytical LLOQ is slightly higher at 0.133 pg/mL [27]. After adjusting for the

4X on-board dilution recommended for plasma samples, the functional LLOQ becomes 0.373

pg/mL.

For the ULOQ determination, the median concentration of the sample with the highest

signals being 460 pg/mL, which gives a functional concentration of 1840 pg/mL after adjusting

for the 4X on-board dilution. However, the highest point in the dynamic range of the assay

calibration curve is 150 pg/mL (600 pg/mL dilution adjusted concentration) and marks the end of

the dynamic range as published by the manufacturer [27]. Thus, 600 pg/mL is the highest point

that can be reliably produced by the assay's calibration curve.

<u>Signal specificity</u>

We compared BD-tau results for equimolar concentrations of the recombinant CNS-

abundant full-length tau441 (2N4R) isoform vs. the much longer big tau isoform commonly

expressed in peripheral tissue in both calibrator diluent (manufacturer recommended) and four-

fold diluted low-concentration QC plasma to account for potential matrix effects. Across three

concentrations tested within the dynamic range of the assay (25 pg/ml, 50 pg/mL, and 100

pg/mL), signals for the 2N4R tau441 isoform increased proportionally to the dilution fold when

diluted in either diluent or QC plasma. However, the big tau isoform signals remained similar to

the blank values [Figure 2, Supplemental Table 5]. This indicates that the assay is highly specific

for CNS-abundant tau isoforms.

<u>Dilution Linearity</u>

Dilution linearity data of three plasma samples were obtained from serial four-fold

dilutions up to 4096-fold [Figure 3A]. Compared with the undiluted stock, the observed

concentrations for all samples at the 4- and 16-fold dilutions were as expected, with measured

values decreasing proportionally. The mean dilution-adjusted relative error was 112% for 4-fold

dilution and 120% for 16-fold dilution [Figure 3B]. For the non-diluted, and 4- and 16-fold

dilutions, the R^2 was 0.908, 0.903, and 0.906 for plasma samples 1, 2, and 3, respectively.

However, after the 64X dilution the samples stopped responding to dilutions. The dilution-

adjusted relative results error showed that beyond 16-fold dilution, the error becomes extremely

high and can potentially lead to falsely high concentrations of plasma BD-tau. Together, the

results show that the BD-tau assay concentrations change linearly with the degree of dilution up

to 16-fold depending on the starting concentration.

<u>Spike Recovery</u>

Spike recovery results were obtained from two different four-fold diluted plasma samples

with non-spiked neat concentrations of 1.19 pg/mL and 1.67 pg/mL for Sample 1 and Sample 2,

respectively. For both samples, recovery was within the 80-120% acceptable range for all

chosen spike concentrations [Figure 4 and Supplemental Table 6].

Plasma/Serum Comparison

Of the n=50 plasma/serum pairs compared, 48 pairs gave values that were eligible for

analysis, as two returned technical errors. Although BD-tau levels were higher in serum vs. in

plasma [Figure 5A], there was a significant positive correlation (Spearman's rho = 0.8392,

p<0.0001) between the levels in the paired samples [Figure 5B].

Sample Stability

Stability of three independent plasma samples was tested after storage in different

temperature conditions and repeated freeze/thaw (f/t) cycles. Normalized concentrations

showed that the storage conditions before moving the sample to -80°C had no impact

[Supplemental Figure 2]. Concerning the impact of f/t cycles, increasing the number of f/t cycles

tended to increase the levels of plasma BD-tau. Friedman test revealed significant differences in

sample concentrations between the freeze thaw cycles (p=0.0004), with Dunn's multiple

comparisons test showing significant differences from the reference sample at f/t cycles number

6 (p=0.0101) and 8 (p=0.0011) [Supplemental Figure 3]. These findings show that plasma

samples for BD-tau measurement should not be exposed to more than four f/t cycles.

Clinical validation in TBI

In the pilot TBI cohort that included n=64 participants with plasma samples, including 34

sTBI participants whose plasma was collected at day 4 post injury, with a subset of 20

additionally having CSF samples [Supplemental Table 2], participants were grouped as

unaffected controls, chronic-mixed TBI (cmTBI), and severe-acute TBI (sTBI). Nonparametric

Kruskal-Wallis one-way ANOVA tests indicated significant differences among the three groups in

both CSF (p=0.0168) and plasma (p<0.0001) BD-tau. Subsequent multiple comparisons test

showed that The Kolmogorov-Smirnov test showed that CSF BD-tau distinguished between

sTBI and other groups (sTBI vs cmTBI, p<0.0001; sTBI vs control, p<0.0001), but not between

cmTBI and controls [Figure 6A]. On the other hand, multiple comparisons tests in CSF did not

reveal any significant differences between controls and either sTBI or cmTBI. However, a

significant difference exists between sTBI and cmTBI (p=0.0286) [Figure 6B]. Overall, the

median BD-tau readings in CSF/plasma pairs were 378 pg/mL and 9.23 pg/mL in CSF and

plasma, respectively, suggesting that ~2.47% (1.62-3.35) of the BD-tau values in CSF are

reflected in plasma for the same individual.

Additionally, in TBI groups, there was an inverse significant correlation between plasma BD-tau

levels and Glasgow Outcome Scale – Extended (GOS-E) scores (spearman rho = -0.6727,

p<0.0001), showing that higher BD-tau levels correspond with worse outcomes. In addition,

there was a significant difference in the GOS-E score between those with sTBI and those with

cmTBI [Supplemental Figure 4]. Moreover, when looking at the cohort, a significant positive

correlation was seen between plasma and CSF BD-tau readings (r=0.6150, p=0.0039).

Supplemental Table 7 summarizes plasma/CSF BD-tau correlations with p-tau217, NfL,

and GFAP, showing strong significant positive correlations in both matrices. In the sTBI group,

BD-tau displayed a significant correlation with p-tau217 in both plasma (p=0.0005) and CSF

(p=0.0002), but with the CSF correlation being understandably stronger than that of plasma

(r=0.9667 and 0.5761, respectively). Similar BD-tau-p-tau217 correlations existed in the control

and cmTBI groups. Plasma BD-tau was correlated with plasma NfL (r=0.8910, p<0.0001) and

GFAP (r=0.5424, p=0.0011) in the sTBI group, whereas correlations in the cmTBI and control

groups did not reach significance.

286   **Discussion**

We have presented an independent validation of the first commercially available BD-tau

assay recently released by the biotech company Quanterix®. BD-tau is a novel blood biomarker

to detect neurodegeneration/brain injury, with promising results published for different

neurological conditions including AD, TBI [6,18,19,21] and stroke [28]. However, previous

studies have used in-house research use only (RUO) assays, with no commercially available

methods to provide widespread standardized access to this biomarker. In the current study, we

evaluated the assay's robustness and precision, spike recovery, dilution linearity, and sample

stability. We also assessed the lot-to-lot comparisons, and correlations in different matrices than

plasma including serum and CSF. Finally, we showed the utility of BD-tau in a clinical TBI

cohort. These findings show that the BD-tau assay fulfills key analytical parameters

recommended by regulatory agencies and neurochemistry expert groups.

The high robustness and precision (based on CVs significantly lower than 20%) show

that the assay test-retest variations are within limits allowable in clinical laboratories within and

between runs [24].

Our results show that plasma samples with high concentrations can be diluted up to 16-

fold (combination of on-board and bench dilutions) and still give reliable concentrations within

the linear range of the calibration curve, with reproducible readings. Further dilution is not

recommended as it may lead to inaccurate signals. Moreover, assay recovery was high; the

concentrations of recombinant tau exogenously added to QC plasma samples were recovered

with 86-96% accuracy.

Additionally, the assay demonstrated selectivity to recombinant 2N4R tau441 vs. big tau

when titrated in buffer or in pooled plasma. The signals of samples spiked with various

concentrations of recombinant peripheral-tau did not differ from the non-spiked samples, both of

which were significantly lower than the corresponding signals for the 2N4R tau441 isoform

which increased proportionally to the spike level.

Our sample stability results showed that as the number of freeze/thaw cycles increases,

the levels of plasma BD-tau tend to increase, with significant increases at 6 and 8 f/t cycles.

This may be due to the disruption of protein complexes that lead to denaturation and release of

free peptides. For storage temperature, our results show that storing samples at room

temperature, 4°C, and -20°C for various periods of time does not significantly impact the levels

of plasma BD-tau in any manner.

We also tested correlations of BD-tau levels in different matrices. Plasma-serum and

CSF-plasma BD-tau pairs demonstrated strong correlations, indicating reliability independent of

matrix choice in alignment with findings from previous studies [6,18,19]. Yet, the absolute

concentrations in serum were significantly higher than those in paired plasma samples, which

contradicts previous findings from an initial assay prototype [18]. In the TBI cohort, group

differences in CSF and plasma were similar, meaning either matrix can be used but should be

used independently in a whole study.

It is noteworthy that, despite being within the error-allowable margin for the tested QC

samples, an unexplained apparent drift in signal was evident when the same samples were

measured in wells at the start vs. at the end of the same plate in an identical run. This drift was

observed when classifying assay signals using either AEBs values or estimated concentrations,

indicating that this issue cannot be explained by potential standard curve signal differences

between plates. Furthermore, our sample stability results showed that sample storage

temperature (4°C or RT) did not impact BD-tau readings. Thus, such drift could not be due to

temperature fluctuations between/during samples preparation and measurement. Additionally,

consistency of the observation across different Simoa HD-X instruments rules out an

instrument-related problem. Finally, paired t-testing on the number of beads for the same QC

samples from the start and end of plates did not reveal statistical differences (p=0.1217),

indicating the drift is likely not attributable to a difference in the amount of capture antibody.

We extended our analytical validation to clinical validation, examining a pilot TBI cohort.

Our results demonstrated the utility of BD-tau in distinguishing individuals with severe traumatic

brain injury at four days post-injury from those with chronic TBI, with only plasma BD-tau

distinguishing severely injured patients from controls. This may be due to the small sample

sizes in CSF groups. Moreover, plasma and CSF BD-tau were correlated, in agreement with

previous findings [6,19,22]. Since BD-tau separated outcome scores of those with chronic from

severe acute brain trauma in both plasma and CSF, BD-tau readings could facilitate predicting

unfavorable outcome and overall clinical management in the acute stages of traumatic brain

injury.

The correlation between plasma BD-tau with NfL and GFAP supports findings in other

studies that BD-tau elevation in TBI can be an indicator of neurodegeneration/neuronal injury

including in response to various processes including microglia activation [6,18,19,21,29]. A

contradictory finding with the literature is the lack of CSF BD-tau correlation with NfL and GFAP

for cmTBI or sTBI [22], perhaps due to the small CSF sample sizes, since they correlate in the

full cohort. Perhaps the most intriguing correlation revealed in this study is the significant

correlation between plasma BD-tau and p-tau217 across the full cohort and the sTBI and control

sub-groups. P-tau217 is one of the most effective predictors of AD and related cognitive decline

[7,30,31]. Larger cohorts are needed to verify these results. Another possibility is combining

these biomarker measurements to help determine whether underlying neurodegeneration is due

to AD when evaluating neurodegenerative diseases [7,21,30–32].

357   **Limitations**

358   Although comprehensive, our study has limitations including our preliminary TBI cohort

359   was relatively small and contained small within-diagnostic group numbers. In addition, the CSF

360   samples were limited, precluding a direct comparison of findings in paired CSF and plasma

361   samples from the same individuals.

Conclusions

In summary, our study provides independent evidence that the plasma BD-tau assay kit

has acceptable analytical performance as well as utility for evaluation of clinical TBI. Our

findings have multiple future implications, including providing the basis for establishing

guidelines for shipping and storage of plasma samples intended to test BD-tau levels. In

addition to analytical findings, our results show that plasma BD-tau levels distinguish between

severe TBI and chronic-mixed TBI, the former of which is associated with worse clinical

outcomes as indicated by GOS-E scores. Thus, our results indicate that immediate BD-tau

readings post-injury may provide an insight into the outcome and therefore allow for the

formulation of an appropriate treatment plan.

<u>Abbreviations:</u> CTE: Chronic traumatic encephalopathy; CV: Coefficient of variation; CVr:

Repeatability coefficient of variation; CVRw: Intermediate precision coefficient of variation;

(U/L)LOQ: (Upper/Lower) limit of quantification; 4-PL: Four-parameter logistic regression; AD:

Alzheimer's Disease; AD8: Ascertain Demential 8 item Questionnaire ; ADRC: Alzheimer's

Disease Research Center; AEB: Average enzyme per bead; APOE: Apolipoprotein E; Aß:

Amyloid beta; BD-tau Adv PLUS: BD-tau Advantage PLUS Kit; BD-tau: Brain-derived tau;

cmTBI: Chronic-mixed TBI; CNS: Central nervous syste; CSF: Cerebrospinal fluid; CT:

computed tomography; EDTA: ethylenediaminetetraacetic acid ; F/T: freeze/thaw; FDA: Food

and Drug Administration; GCS: Glasgow Coma Scale; GFAP: Glial-fibrillary acidic protein; GOS-

E: Glasgow Outcome Scale - Extended Version; HD-X: Quanterix®'s trademark name for their

instrument; NfL: neurofilament light chain; p-tau: phosphorylated tau; QC: Quality control;

Simoa: Single-molecule array; sTBI: Severe-acute TBI; TBI: Traumatic brain injury; t-tau: Total

tau; UCH-L1: Ubiquitin C-terminal hydrolase-L1.

<u>Human Genes:</u> *APOE:* Apolipoprotein E

Declarations

<u>Ethics approval and consent to participate:</u>

All patient samples were obtained with full written informed consent and approved by the

University of Pittsburgh Institutional Review Board (ADRC study: MOD19110245-023; BTRC

study: 19030228; Military CTE study: 19110161)

<u>Consent for publication:</u>

Not applicable.

<u>Availability of data and materials</u>

De-identified data generated in this study can be shared with qualified and identifiable

investigators for the purpose of replicating the results and procedures in the study. Requests

can be made to the corresponding author of the present study (T.K.K.) who will refer them to the

respective cohort principal investigators where necessary. Requests will be reviewed by the

investigators and respective institutions to ensure that each data request and transfer are in

agreement with US legislation on general data protection or is subject to any intellectual

property or confidentiality obligations. The purpose of these procedures is to ensure participant

anonymity and ensure data safeguarding limited to the terms set forth in the IRB approvals.

Data request can be made directly at https://www.adrc.pitt.edu/for-researchers/adrc-data-

resources/ for Pittsburgh ADRC.

<u>Competing interests</u>

Thomas K. Karikari: TKK has consulted for Quanterix Corporation, SpearBio Inc., Neurogen

Biomarking LLC., and Alzheon, has served on advisory boards for Siemens Healthineers and

Neurogen Biomarking LLC., outside the submitted work. He has received in-kind research

support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well

as meeting travel support from the Alzheimer's Association and Neurogen Biomarking LLC.,

outside the submitted work. TKK has received royalties from Bioventix for the transfer of specific

antibodies and assays to third party organizations. He has received honoraria for speaker/grant

review engagements from the NIH, UPENN, UW-Madison, the Cherry Blossom symposium, the

HABS-HD/ADNI4 Health Enhancement Scientific Program, Advent Health Translational

Research Institute, Brain Health conference, Barcelona-Pittsburgh conference, the International

Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec

Center for Drug Discovery, Canada, all outside of the submitted work. TKK is an inventor on

several patents and provisional patents regarding biofluid biomarker methods, targets and

reagents/compositions, that may generate income for the institution and/or self should they be

licensed and/or transferred to another organization. These include WO2020193500A1: Use of a

ps396 assay to diagnose tauopathies; US 63/679,361: Methods to Evaluate Early-Stage Pre-

Tangle TAU Aggregates and Treatment of Alzheimer's Disease Patients; US 63/672,952:

Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer's Disease; US

63/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric

tau and soluble tau aggregates.

Funding:

TKK and the Karikari Laboratory members were supported by NIH/NIA (R01 AG083874,

U24AG082930, P30 AG066468, RF1 AG077474, R01 AG083156, R37 AG023651, R01

AG025516, R01 AG073267, R01 AG075336, R01 AG072641, P01 AG025204), NIH/NINDS (U01

NS131740, U01 NS141777), NIH/NIMH (R01 MH108509), Aging Mind Foundation

(DAF2255207), DoD (HT94252320064), the Anbridge Charitable Fund, and a professorial

endowment from the Department of Psychiatry, University of Pittsburgh. The content of this article

is solely the responsibility of the authors and does not necessarily represent the official views of

the funders.

Authors' contributions:

TKK, MNN, and XZ contributed to the study's conception and design. MNN ran biochemical

assays on TBI and ADRC cohorts, performed data analysis and produced the figures. ADC,

AMP, DOO, JKK, SES, OLL, XZ, and YC provided review and feedback on manuscript contents.

YC provided plasma/serum ADRC samples used in matrix comparisons. AMP, DOO, and SES

provided samples from TBI and BTRC cohort used in clinical validation. SES contributed to

writing the methods and provided participant information for the TBI and BTRC cohorts. All

authors contributed to and approved the final version of the manuscript.

Acknowledgements:

We express our appreciation to the Karikari Laboratory members, our collaborators at the Pitt-

ADRC and the Puccio Laboratory.

References

1. Lleó, A. Biomarkers in neurological disorders: a fast-growing market. *Brain Commun* **3**,

fcab086 (2021).

2. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework.

Clinical Pharmacology & Therapeutics **69**, 89–95 (2001).

3. Lleó, A. *et al.* Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Nat Rev Neurol **11**, 41–55 (2015).

4. Shoji, M. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy. in *Tau*

Biology (eds Takashima, A., Wolozin, B. & Buee, L.) 393–405 (Springer, Singapore, 2019).

doi:10.1007/978-981-32-9358-8_29.

5. Hampel, H. & Blennow, K. CSF tau and β-amyloid as biomarkers for mild cognitive

impairment. *Dialogues Clin Neurosci* **6**, 379–390 (2004).

6. Gonzalez-Ortiz, F. *et al.* Brain-derived tau: a novel blood-based biomarker for Alzheimer's

disease-type neurodegeneration. *Brain* **146**, 1152–1165 (2023).

7. Telser, J., Risch, L., Saely, C. H., Grossmann, K. & Werner, P. P-tau217 in Alzheimer's

disease. *Clinica Chimica Acta* **531**, 100–111 (2022).

8. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma

biomarkers in Alzheimer disease. *Nat Rev Neurol* **6**, 131–144 (2010).

9. Brum, W. S. *et al.* Biological variation estimates of Alzheimer's disease plasma biomarkers

in healthy individuals. *Alzheimer's & Dementia* **20**, 1284–1297 (2024).

10. Noda, K., Lim, Y., Goto, R., Sengoku, S. & Kodama, K. Cost-effectiveness comparison

between blood biomarkers and conventional tests in Alzheimer's disease diagnosis. *Drug*

Discovery Today **29**, 103911 (2024).

11. Krawczuk, D., Kulczyńska-Przybik, A. & Mroczko, B. Clinical Application of Blood

Biomarkers in Neurodegenerative Diseases—Present and Future Perspectives. *Int J Mol*

Sci **25**, 8132 (2024).

12. Hardy-Sosa, A. *et al.* Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic

Review. *Front Aging Neurosci* **14**, 683689 (2022).

13. Shi, M., Chu, F., Zhu, F. & Zhu, J. Peripheral blood amyloid-β involved in the pathogenesis

of Alzheimer's disease via impacting on peripheral innate immune cells. *Journal of*

Neuroinflammation **21**, 5 (2024).

14. Xu, B. *et al.* Peripheral proteinopathy in neurodegenerative diseases. *Transl Neurodegener*

14, 2 (2025).

15. Dugger, B. N. *et al.* The Presence of Select Tau Species in Human Peripheral Tissues and

Their Relation to Alzheimer's Disease. *Journal of Alzheimer's Disease* **51**, 345–356 (2016).

16. Balczon, R. *et al.* Lung endothelium, tau, and amyloids in health and disease. *Physiological*

Reviews **104**, 533–587 (2024).

17. Zetterberg, H. *et al.* Plasma tau levels in Alzheimer's disease. *Alzheimer's Research &*

Therapy **5**, 9 (2013).

18. Gonzalez-Ortiz, F. *et al.* Preanalytical stability of plasma/serum brain-derived tau.

Alzheimer's & Dementia **19**, 4764–4770 (2023).

19. Gonzalez-Ortiz, F. *et al.* Plasma brain-derived tau is an amyloid-associated

neurodegeneration biomarker in Alzheimer's disease. *Nat Commun* **15**, 2908 (2024).

20. Clemmensen, F. K. *et al.* The plasma p-tau217/BD-tau ratio improves biomarker short-term

variability in memory clinic patients. *Alzheimer's & Dementia: Translational Research &*

Clinical Interventions **11**, e70143 (2025).

21. Gonzalez-Ortiz, F. *et al.* Levels of plasma brain-derived tau and p-tau181 in Alzheimer's

disease and rapidly progressive dementias. *Alzheimer's & Dementia* **20**, 745–751 (2024).

22. Gonzalez-Ortiz, F. *et al.* Association of Serum Brain-Derived Tau With Clinical Outcome and

Longitudinal Change in Patients With Severe Traumatic Brain Injury. *JAMA Network Open* **6**,

e2321554 (2023).

23. Research, C. for D. E. and. Bioanalytical Method Validation Guidance for Industry.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-

method-validation-guidance-industry (2020).

24. Andreasson, U. *et al.* A Practical Guide to Immunoassay Method Validation. *Front Neurol* **6**,

179 (2015).

25. Chen, Y. *et al.* Equivalence of plasma and serum for clinical measurement of p-tau217:

comparative analyses of four blood-based assays. *medRxiv* 2024.12.26.24319657 (2024)

doi:10.1101/2024.12.26.24319657.

26. Zeng, X. *et al.* Alzheimer blood biomarkers: practical guidelines for study design, sample

collection, processing, biobanking, measurement and result reporting. *Molecular*

Neurodegeneration **19**, 40 (2024).

27. BD-Tau Assay Kit -- Quanterix. *Quanterix* https://www.quanterix.com/simoa-assay-kits/bd-

tau/ (2024).

28. Gundersen, J. K. *et al.* Neuronal plasma biomarkers in acute ischemic stroke. *J Cereb*

Blood Flow Metab **45**, 77–84 (2025).

29. Leipp, F. *et al.* Glial fibrillary acidic protein in Alzheimer's disease: a narrative review. *Brain*

Communications **6**, fcae396 (2024).

30. Palmqvist, S. *et al.* Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer

Disease vs Other Neurodegenerative Disorders. *JAMA* **324**, 772 (2020).

31. Mattsson-Carlgren, N. *et al.* Prediction of Longitudinal Cognitive Decline in Preclinical

Alzheimer Disease Using Plasma Biomarkers. *JAMA Neurol* **80**, 360–369 (2023).

32. Asken, B. M. *et al.* Plasma P-tau181 and P-tau217 in Patients With Traumatic

Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.

Neurology **99**, e594–e604 (2022).

 Figure legends

Figure 1. Robustness and precision of plasma BD-tau.

(A) Plot showing pooled data across 10 independent runs for three different pre-made QC

samples. Each sample was measured in duplicates at the start and at the end of the plate. The

mean values at the start (solid) vs. the end (hollow) for readings from the same plate are shown.

(B) Plot of the overall average readings for each QC per plate (combining the duplicate readings

at the start and at the end). (C) Normalized plasma BD-tau concentrations for the five samples

evaluated in the precision experiments. Single-use aliquots of each specimen were measured 25

individual times, across five runs over five different days. For each sample, the black dots show

the individual concentrations in a single precision run, the bars show the median, and error bars

show the inter-quartile range (IQR). (D) Measured (without normalization) sample concentrations

in the precision experiments.

Figure 2. BD-tau assay specificity.

Comparison of BD-tau assay readings when measured in equal concentrations of recombinant

forms of 2N4R CNS-abundant tau441 and the peripherally-enriched big tau isoform. The test

proteins were evaluated in two separate experimental conditions involving three theoretical

concentrations of the recombinant protein and the non-spiked matrix for background signal: (1)

dilution in the calibrator diluent following the manufacturer recommendations, and (2) four-fold

dilution in QC plasma to account for potential matrix effects.

Figure 3. Dilution linearity of plasma BD-tau.

A) Portrayal of dilution linearity of plasma samples showing the concentration from non-diluted

(ND) up to 4096-fold diluted, across four-fold stepwise decreases. B) The dilution-adjusted

relative errors at 4- and 16-fold dilutions for samples showing the adjustment which produced

concentration within ±20% the normalized concentration of the dilution-free (neat) sample

(shown as dotted red lines at 80% and 120%). Dilutions beyond 16-fold are not shown since

their normalized concentration exceeded 140%.

Figure 4. Spike recovery of plasma BD-tau.

Spike recovery in two four-fold diluted plasma samples at four different spike levels. The bars

indicate the percentage recovery in each sample at the given spike level, and the red dotted

lines at 80% and 120% show the acceptable range of recovery as described by field experts

[24].

Figure 5. Comparison of BD-tau levels in paired plasma vs. serum samples.

(A) Comparison of the absolute concentrations of BD-tau in paired plasma/serum samples from

the University of Pittsburgh ADRC (n=48 viable pairs from a cohort of n=50). (B) Spearman

correlation between plasma and serum BD-tau concentrations. Each point represents a

plasma/serum pair, shown in red is the linear regression line.

Figure 6. Clinical validation of plasma and CSF BD-tau in the pilot TBI cohort.

BD-tau readings for control, chronic-mixed TBI (cmTBI), and severe-acute TBI (sTBI)

participants from a pilot cohort in both CSF (A) and plasma (B), plotted on a log(10) scale. All

data points are shown. Kruskal-Wallis multiple comparisons tests are shown comparing group

BD-tau distributions where significant differences are seen.

A Within-Plate Robustness

B Between-Plate Robustness

C Precision - Normalized

D Endogenous Sample Concentrations

Specificity

A

Plasma vs Serum

0.0001

B

Plasma vs Serum

r = 0.8392
p<0.0001